Estrogen attenuates manganese-induced glutamate transporter impairment in rat primary astrocytes

Eunsook Lee, Marta Sidoryk-Wegrzynowicz, Marcelo Farina, Joao B T Rocha, Michael Aschner

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

The astrocytic glutamate transporters (GLT-1, GLAST) are critical for removing excess glutamate from synaptic sites, thereby maintaining glutamate homeostasis within the brain. 17β-Estradiol (E2) is one of the most active estrogen hormones possessing neuroprotective effects both in in vivo and in vitro models, and it has been shown to enhance astrocytic glutamate transporter function (Liang et al. in J Neurochem 80:807-814, 2002; Pawlak et al. in Brain Res Mol Brain Res 138:1-7, 2005). However, E2 is not clinically optimal for neuroprotection given its peripheral feminizing and proliferative effects; therefore, brain selective estrogen receptor modulators (neuro SERMs) (Zhao et al. in Neuroscience 132:299-311, 2005) that specifically target estrogenic mechanisms, but lack the systemic estrogen side effects offer more promising therapeutic modality for the treatment of conditions associated with excessive synaptic glutamate levels. This review highlights recent studies from our laboratory showing that E2 and SERMs effectively reverse glutamate transport inhibition in a manganese (Mn)-induced model of glutamatergic deregulation. Specifically, we discuss mechanisms by which E2 restores the expression and activity of glutamate uptake. We advance the hypothesis that E2 and related compounds, such as tamoxifen may offer a potential therapeutic modality in neurodegenerative disorders, which are characterized by altered glutamate homeostasis.

Original languageEnglish (US)
Pages (from-to)124-130
Number of pages7
JournalNeurotoxicity Research
Volume23
Issue number2
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Amino Acid Transport System X-AG
Manganese
Astrocytes
Rats
Glutamic Acid
Estrogens
Selective Estrogen Receptor Modulators
Brain
Homeostasis
Deregulation
Neuroprotective Agents
Tamoxifen
Neurosciences
Neurodegenerative Diseases
Estradiol
Hormones
Therapeutics

Keywords

  • Astrocyte
  • Estrogen
  • GLAST
  • GLT-1
  • Glutamate
  • Manganese
  • Neuroprotection

ASJC Scopus subject areas

  • Neuroscience(all)
  • Medicine(all)
  • Toxicology

Cite this

Estrogen attenuates manganese-induced glutamate transporter impairment in rat primary astrocytes. / Lee, Eunsook; Sidoryk-Wegrzynowicz, Marta; Farina, Marcelo; Rocha, Joao B T; Aschner, Michael.

In: Neurotoxicity Research, Vol. 23, No. 2, 2013, p. 124-130.

Research output: Contribution to journalReview article

Lee, Eunsook ; Sidoryk-Wegrzynowicz, Marta ; Farina, Marcelo ; Rocha, Joao B T ; Aschner, Michael. / Estrogen attenuates manganese-induced glutamate transporter impairment in rat primary astrocytes. In: Neurotoxicity Research. 2013 ; Vol. 23, No. 2. pp. 124-130.
@article{4b2e9517e74b4627a920ea1a0f96c94f,
title = "Estrogen attenuates manganese-induced glutamate transporter impairment in rat primary astrocytes",
abstract = "The astrocytic glutamate transporters (GLT-1, GLAST) are critical for removing excess glutamate from synaptic sites, thereby maintaining glutamate homeostasis within the brain. 17β-Estradiol (E2) is one of the most active estrogen hormones possessing neuroprotective effects both in in vivo and in vitro models, and it has been shown to enhance astrocytic glutamate transporter function (Liang et al. in J Neurochem 80:807-814, 2002; Pawlak et al. in Brain Res Mol Brain Res 138:1-7, 2005). However, E2 is not clinically optimal for neuroprotection given its peripheral feminizing and proliferative effects; therefore, brain selective estrogen receptor modulators (neuro SERMs) (Zhao et al. in Neuroscience 132:299-311, 2005) that specifically target estrogenic mechanisms, but lack the systemic estrogen side effects offer more promising therapeutic modality for the treatment of conditions associated with excessive synaptic glutamate levels. This review highlights recent studies from our laboratory showing that E2 and SERMs effectively reverse glutamate transport inhibition in a manganese (Mn)-induced model of glutamatergic deregulation. Specifically, we discuss mechanisms by which E2 restores the expression and activity of glutamate uptake. We advance the hypothesis that E2 and related compounds, such as tamoxifen may offer a potential therapeutic modality in neurodegenerative disorders, which are characterized by altered glutamate homeostasis.",
keywords = "Astrocyte, Estrogen, GLAST, GLT-1, Glutamate, Manganese, Neuroprotection",
author = "Eunsook Lee and Marta Sidoryk-Wegrzynowicz and Marcelo Farina and Rocha, {Joao B T} and Michael Aschner",
year = "2013",
doi = "10.1007/s12640-012-9347-2",
language = "English (US)",
volume = "23",
pages = "124--130",
journal = "Neurotoxicity Research",
issn = "1029-8428",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Estrogen attenuates manganese-induced glutamate transporter impairment in rat primary astrocytes

AU - Lee, Eunsook

AU - Sidoryk-Wegrzynowicz, Marta

AU - Farina, Marcelo

AU - Rocha, Joao B T

AU - Aschner, Michael

PY - 2013

Y1 - 2013

N2 - The astrocytic glutamate transporters (GLT-1, GLAST) are critical for removing excess glutamate from synaptic sites, thereby maintaining glutamate homeostasis within the brain. 17β-Estradiol (E2) is one of the most active estrogen hormones possessing neuroprotective effects both in in vivo and in vitro models, and it has been shown to enhance astrocytic glutamate transporter function (Liang et al. in J Neurochem 80:807-814, 2002; Pawlak et al. in Brain Res Mol Brain Res 138:1-7, 2005). However, E2 is not clinically optimal for neuroprotection given its peripheral feminizing and proliferative effects; therefore, brain selective estrogen receptor modulators (neuro SERMs) (Zhao et al. in Neuroscience 132:299-311, 2005) that specifically target estrogenic mechanisms, but lack the systemic estrogen side effects offer more promising therapeutic modality for the treatment of conditions associated with excessive synaptic glutamate levels. This review highlights recent studies from our laboratory showing that E2 and SERMs effectively reverse glutamate transport inhibition in a manganese (Mn)-induced model of glutamatergic deregulation. Specifically, we discuss mechanisms by which E2 restores the expression and activity of glutamate uptake. We advance the hypothesis that E2 and related compounds, such as tamoxifen may offer a potential therapeutic modality in neurodegenerative disorders, which are characterized by altered glutamate homeostasis.

AB - The astrocytic glutamate transporters (GLT-1, GLAST) are critical for removing excess glutamate from synaptic sites, thereby maintaining glutamate homeostasis within the brain. 17β-Estradiol (E2) is one of the most active estrogen hormones possessing neuroprotective effects both in in vivo and in vitro models, and it has been shown to enhance astrocytic glutamate transporter function (Liang et al. in J Neurochem 80:807-814, 2002; Pawlak et al. in Brain Res Mol Brain Res 138:1-7, 2005). However, E2 is not clinically optimal for neuroprotection given its peripheral feminizing and proliferative effects; therefore, brain selective estrogen receptor modulators (neuro SERMs) (Zhao et al. in Neuroscience 132:299-311, 2005) that specifically target estrogenic mechanisms, but lack the systemic estrogen side effects offer more promising therapeutic modality for the treatment of conditions associated with excessive synaptic glutamate levels. This review highlights recent studies from our laboratory showing that E2 and SERMs effectively reverse glutamate transport inhibition in a manganese (Mn)-induced model of glutamatergic deregulation. Specifically, we discuss mechanisms by which E2 restores the expression and activity of glutamate uptake. We advance the hypothesis that E2 and related compounds, such as tamoxifen may offer a potential therapeutic modality in neurodegenerative disorders, which are characterized by altered glutamate homeostasis.

KW - Astrocyte

KW - Estrogen

KW - GLAST

KW - GLT-1

KW - Glutamate

KW - Manganese

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=84984576833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984576833&partnerID=8YFLogxK

U2 - 10.1007/s12640-012-9347-2

DO - 10.1007/s12640-012-9347-2

M3 - Review article

AN - SCOPUS:84984576833

VL - 23

SP - 124

EP - 130

JO - Neurotoxicity Research

JF - Neurotoxicity Research

SN - 1029-8428

IS - 2

ER -